CLSI Part of Winning Consortium to Develop the West Coast Accelerator for Anti-Microbial Resistance (AMR)
The California Life Sciences Institute is part of a consortium awarded $30 million by the Biomedical Advanced Research Authority (BARDA) to accelerate a portfolio of innovative antibacterial products. CARB-X – the Combatting Antibiotic-Resistant Bacteria Accelerator – is the world’s largest public-private partnership dedicated to combatting antibiotic resistance. Formed by Boston University, the consortium consists of two accelerators in the US (CLSI and MassBio) and two in the UK (The Wellcome Trust and the AMR Centre), the Broad Institute, RTI International, BARDA and the National Institute of Allergy and Infectious Disease (NIAID). In year one, CARB-X will contribute $40 million dollars to the effort in addition to the funding from BARDA.
With resistance to antibiotics emerging as one of the most significant threats to global public health, the program provides up to $350M over five years to rejuvenate the antimicrobial pipeline. The Accelerators will provide non-dilutive funding, R&D support and business mentoring to ensure that promising technologies are rapidly transitioned through the proof of concept phase into product candidates and the clinic. CLSI will manage a minimum of five early stage programs. Successful companies will emerge from CARB-X as graduates with resources, networks and a robust product development strategy to support further clinical development. Products may include therapeutics, diagnostics, vaccines or devices.
CLSI will serve accepted participants from across the state and country. It is currently spearheaded by the new Senior Director of CLSI CARB-X, Heather Shane, for questions, please contact email@example.com.